INMB Stock Price, Chart, Stats & News

INmune Bio, Inc.
Save
38.02M
Market cap
–
Current P/E
–
Forward P/E
INMB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 44.00% |
Operating margin | -102752.00% |
Pretax margin | -99774.00% |
Net margin | -99774.00% |
Effective tax rate | – |
ROA | -149.55% |
ROE | -172.00% |
D/E | 0.04x |
Interest coverage ratio | – |
INMB valuation
P/E | – |
P/S | 595.51x |
P/B | 1.17x |
P/CF | -0.97x |
P/FCF | -0.94x |
P/OCF | -0.97x |
PEG | -0.04x |
EV multiple | -1.68x |
About
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases.
Similar securities
Based on sector and market capitalization
Report issue











